https://www.selleckchem.com/products/rki-1447.html
To assess cardiac safety in COVID-19 patients treated with the combination of Hydroxychloroquine and Azithromycin using arrhythmia risk management plan. We retrospectively examined arrhythmia safety of treatment with Hydroxychloroquine and Azithromycin in the setting of pre-defined arrhythmia risk management plan. The data was analyzed using R statistical package version 4.0.0. A two-tailed p-value0.05 was considered significant. 81 patients were included from March 23rd to May 10th 2020. The median age was 59years, 58.0% were fema
Like
Comment
Share
